Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Actuate TherapeuticsACTU -3.29%14 Price-to-Tangible-Book is 25.12 as of Sep. 15, 2026. GuruFocus rates ACTU with a GF Score™ of 14/100. Among 1,135 Biotechnology companies, Actuate Therapeutics ranks worse than 95.15% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Actuate Therapeutics Price-to-Tangible-Book Related Terms
Actuate Therapeutics Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Actuate Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACTU vs CRVO, KPTI, ALGS: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Actuate Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Actuate Therapeutics Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Actuate Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Actuate Therapeutics (ACTU) has a Price-to-Tangible-Book of 25.12 as of Sep. 15, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Actuate Therapeutics and its competitors. According to the industry distribution chart, Actuate Therapeutics ranks #1080 out of 1135 companies in the Biotechnology industry, placing it in the top 95.2%.
Is Actuate Therapeutics' Price-to-Tangible-Book too high?
Actuate Therapeutics' current Price-to-Tangible-Book is 25.12. The Biotechnology industry median Price-to-Tangible-Book is 3.31. Actuate Therapeutics' value of 25.12 is 658.9% above this industry median. Based on the distribution chart, Actuate Therapeutics ranks #1080 out of 1135 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' Price-to-Tangible-Book compare to CRVO and KPTI?
According to the Biotechnology industry distribution chart, Actuate Therapeutics ranks #1080 out of 1135 companies for Price-to-Tangible-Book. This places Actuate Therapeutics in the lower half of its industry. The industry median Price-to-Tangible-Book is 3.31. Actuate Therapeutics' value of 25.12 is 658.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.31, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Actuate Therapeutics's current Price-to-Tangible-Book of 25.12 is 658.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Actuate Therapeutics and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actuate Therapeutics's current Price-to-Tangible-Book is 25.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current Price-to-Tangible-Book of 25.12. The current Price-to-Tangible-Book is 25.12 and 658.9% above the Biotechnology industry median of 3.31. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current Price-to-Tangible-Book is 25.12 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score
Get the complete analysis for ACTU
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACTU has been successfully added to your 
